BioCentury
ARTICLE | Company News

Achillion, J&J deal

May 25, 2015 7:00 AM UTC

Achillion granted Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit exclusive, worldwide rights to develop and commercialize treatment regimens containing Achillion’s HCV assets. Achillion’s HCV pipeline includes ACH-3102, a pan-genotypic, second-generation HCV NS5A protein inhibitor; ACH-3422, a small molecule nucleotide prodrug inhibitor of HCV NS5B; and sovaprevir, a selective inhibitor of HCV NS3 protease. J&J will be responsible for manufacturing, development and commercialization costs related to the HCV compounds. ...